Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic Profiling
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
The current consensus recognizes four main medulloblastoma subgroups (wingless, Sonic hedgehog, group 3 and group 4). While medulloblastoma subgroups have been characterized extensively at the (epi-)genomic and transcriptomic levels, the proteome and phosphoproteome landscape remain to be comprehensively elucidated. Using quantitative (phospho)-proteomics in primary human medulloblastomas, we unravel distinct posttranscriptional regulation leading to highly divergent oncogenic signaling and kinase activity profiles in groups 3 and 4 medulloblastomas. Specifically, proteomic and phosphoproteomic analyses identify aberrant ERBB4-SRC signaling in group 4. Hence, enforced expression of an activated SRC combined with p53 inactivation induces murine tumors that resemble group 4 medulloblastoma. Therefore, our integrative proteogenomics approach unveils an oncogenic pathway and potential therapeutic vulnerability in the most common medulloblastoma subgroup.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Szklarczyk, D., Morris, J. H., Cook, H., Kuhn, M., Wyder, S., Simonovic, M., Santos, A., Doncheva, N. T., Roth, A., Bork, P., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw937 · Cited by 6,980
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566
Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E., & Storey, J. D. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts034 · Cited by 6,231
Wallace, D. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3365 · Cited by 2,404 · cited 2×
“G3 displayed activation of the following kinases: the PDHK family, involved in mitochondrial metabolic regulation (Wallace, 2012); and the CLK and CK2 families, involved in RNA splicing (Araki et al., 2015; Bian et al., 2013).”
BackgroundEnrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and Interpretation
Merico, D., Isserlin, R., Stueker, O., Emili, A., & Bader, G. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013984 · Cited by 2,235 · cited 2×
“4.0 Shannon et al., 2003 http://www.cytoscape.org Enrichment map Merico et al., 2010 http://apps.cytoscape.org/apps/enrichmentmap ROMA Martignetti et al., 2016 https://github.com/Rbbt-Workflows/ROMA Similarity Network Fusion (SNF) Wang et al., 2014…”
BackgroundMethodInfluential
Research works printed but not linked: 60
- Araki, 2015, Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing, PLoS One, 10, e0116929, 10.1371/journal.pone.0116929 · DOI
- Archer, 2018, Proteomics, post-translational modifications, and integrative analyses reveal heterogeneity of molecular mechanisms within medulloblastoma subgroups, Cancer Cell, 34, 396, 10.1016/j.ccell.2018.08.004 · DOI · Paper page
- Bennetzen, 2012, PhosphoSiteAnalyzer: a bioinformatic platform for deciphering phospho proteomes using kinase predictions retrieved from NetworKIN, J. Proteome Res., 11, 3480, 10.1021/pr300016e · DOI
- Bian, 2013, Global screening of CK2 kinase substrates by an integrated phosphoproteomics workflow, Sci. Rep., 3, 3460, 10.1038/srep03460 · DOI
- Cho, 2011, Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome, J. Clin. Oncol., 29, 1424, 10.1200/JCO.2010.28.5148 · DOI · Paper page
- Chou, 2011, Biological sequence motif discovery using motif-x, Curr. Protoc. Bioinformatics, 13, 15
- Clifford, 2006, Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis, Cell Cycle, 5, 2666, 10.4161/cc.5.22.3446 · DOI · Paper page
- Dobin, 2013, STAR: ultrafast universal RNA-seq aligner, Bioinformatics, 29, 15, 10.1093/bioinformatics/bts635 · DOI · Paper page
- Durinck, 2009, Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt, Nat. Protoc., 4, 1184, 10.1038/nprot.2009.97 · DOI · Paper page
- Fabregat, 2016, The reactome pathway knowledgebase, Nucleic Acids Res., 44, D481, 10.1093/nar/gkv1351 · DOI · Paper page
- Fan, 2016, Characterizing transcriptional heterogeneity through pathway and gene set overdispersion analysis, Nat. Methods, 13, 241, 10.1038/nmeth.3734 · DOI · Paper page
- Geiger, 2010, Super-SILAC mix for quantitative proteomics of human tumor tissue, Nat. Methods, 7, 383, 10.1038/nmeth.1446 · DOI · Paper page
- Geiger, 2011, Use of stable isotope labeling by amino acids in cell culture as a spike-in standard in quantitative proteomics, Nat. Protoc., 6, 147, 10.1038/nprot.2010.192 · DOI · Paper page
- Gilbertson, 1998, Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma, Cancer Res., 58, 3932
- Gilbertson, 1997, Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma, Cancer Res., 57, 3272
- Gottardo, 2014, Medulloblastoma down under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group, Acta Neuropathol., 127, 189, 10.1007/s00401-013-1213-7 · DOI
- Guo, 2017, Proteasome activator subunit 3 promotes pancreatic cancer growth via c-Myc-glycolysis signaling axis, Cancer Lett., 386, 161, 10.1016/j.canlet.2016.08.018 · DOI
- Horn, 2014, KinomeXplorer: an integrated platform for kinome biology studies, Nat. Methods, 11, 603, 10.1038/nmeth.2968 · DOI · Paper page
- Hovestadt, 2014, Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing, Nature, 510, 537, 10.1038/nature13268 · DOI · Paper page
- Hovestadt, 2013, Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays, Acta Neuropathol., 125, 913, 10.1007/s00401-013-1126-5 · DOI · Paper page
- Karaki, 2015, The eukaryotic translation initiation factor 4E (eIF4E) as a therapeutic target for cancer, Adv. Protein Chem. Struct. Biol., 101, 1, 10.1016/bs.apcsb.2015.09.001 · DOI
- Kawauchi, 2017, Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells, Oncogene, 36, 5231, 10.1038/onc.2017.110 · DOI
- Kool, 2014, Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition, Cancer Cell, 25, 393, 10.1016/j.ccr.2014.02.004 · DOI · Paper page
- Kool, 2012, Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas, Acta Neuropathol., 123, 473, 10.1007/s00401-012-0958-8 · DOI · Paper page
- Kool, 2008, Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features, PLoS One, 3, e3088, 10.1371/journal.pone.0003088 · DOI · Paper page
- Lan, 2017, Downregulation of β-arrestin 1 suppresses glioblastoma cell malignant progression vis inhibition of Src signaling, Exp. Cell Res., 357, 51, 10.1016/j.yexcr.2017.04.023 · DOI
- Langmead, 2012, Fast gapped-read alignment with Bowtie 2, Nat. Methods, 9, 357, 10.1038/nmeth.1923 · DOI · Paper page
- Lin, 2016, Active medulloblastoma enhancers reveal subgroup-specific cellular origins, Nature, 530, 57, 10.1038/nature16546 · DOI · Paper page
- Louis, 2016, The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol, 131, 803, 10.1007/s00401-016-1545-1 · DOI · Paper page
- Martignetti, 2016, ROMA: representation and quantification of module activity from target expression data, Front. Genet., 7, 18, 10.3389/fgene.2016.00018 · DOI
- Milde, 2012, HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment, J. Neurooncol., 110, 335, 10.1007/s11060-012-0978-1 · DOI
- Northcott, 2011, Medulloblastoma comprises four distinct molecular variants, J. Clin. Oncol., 29, 1408, 10.1200/JCO.2009.27.4324 · DOI · Paper page
- Northcott, 2012, Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples, Acta Neuropathol., 123, 615, 10.1007/s00401-011-0899-7 · DOI · Paper page
- Obara, 2004, PKA phosphorylation of Src mediates Rap1 activation in NGF and cAMP signaling in PC12 cells, J. Cell Sci., 117, 6085, 10.1242/jcs.01527 · DOI · Paper page
- Pei, 2012, An animal model of MYC-driven medulloblastoma, Cancer Cell, 21, 155, 10.1016/j.ccr.2011.12.021 · DOI · Paper page
- Pfister, 2009, Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci, J. Clin. Oncol., 27, 1627, 10.1200/JCO.2008.17.9432 · DOI · Paper page
- Poullet, 2007, myProMS, a web server for management and validation of mass spectrometry-based proteomic data, Proteomics, 7, 2553, 10.1002/pmic.200600784 · DOI · Paper page
- Remke, 2011, FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma, J. Clin. Oncol., 29, 3852, 10.1200/JCO.2011.36.2798 · DOI · Paper page
- Remke, 2011, Adult medulloblastoma comprises three major molecular variants, J. Clin. Oncol., 29, 2717, 10.1200/JCO.2011.34.9373 · DOI · Paper page
- Ritchie, 2015, Limma powers differential expression analyses for RNA-sequencing and microarray studies, Nucleic Acids Res., 43, e47, 10.1093/nar/gkv007 · DOI · Paper page
- Robinson, 2012, Novel mutations target distinct subgroups of medulloblastoma, Nature, 488, 43, 10.1038/nature11213 · DOI · Paper page
- Sato, 2007, Stable integration and conditional expression of electroporated transgenes in chicken embryos, Dev. Biol., 305, 616, 10.1016/j.ydbio.2007.01.043 · DOI · Paper page
- Schwalbe, 2017, Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study, Lancet Oncol., 18, 958, 10.1016/S1470-2045(17)30243-7 · DOI · Paper page
- Schwalbe, 2013, DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies, Acta Neuropathol., 125, 359, 10.1007/s00401-012-1077-2 · DOI · Paper page
- Shannon, 2003, Cytoscape: a software environment for integrated models of biomolecular interaction networks, Genome Res., 13, 2498, 10.1101/gr.1239303 · DOI · Paper page
- Shih, 2014, Cytogenetic prognostication within medulloblastoma subgroups, J. Clin. Oncol., 32, 886, 10.1200/JCO.2013.50.9539 · DOI · Paper page
- Sturm, 2016, New brain tumor entities emerge from molecular classification of CNS-PNETs, Cell, 164, 1060, 10.1016/j.cell.2016.01.015 · DOI · Paper page
- Sugimura, 2000, Mutation of the SRC gene in endometrial carcinoma, Jpn. J. Cancer Res., 91, 395, 10.1111/j.1349-7006.2000.tb00958.x · DOI · Paper page
- Taus, 2011, Universal and confident phosphorylation site localization using phosphoRS, J. Proteome Res., 10, 5354, 10.1021/pr200611n · DOI · Paper page
- Thompson, 2006, Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations, J. Clin. Oncol., 24, 1924, 10.1200/JCO.2005.04.4974 · DOI · Paper page
- Thoreen, 2017, The molecular basis of mTORC1-regulated translation, Biochem. Soc. Trans., 45, 213, 10.1042/BST20160072 · DOI · Paper page
- Truitt, 2017, New frontiers in translational control of the cancer genome, Nat. Rev. Cancer, 17, 332, 10.1038/nrc.2017.30 · DOI · Paper page
- Vizcaino, 2016, 2016 update of the PRIDE database and its related tools, Nucleic Acids Res., 44, 11033, 10.1093/nar/gkw880 · DOI · Paper page
- Wang, 2016, Transactivation of epidermal growth factor receptor by G protein-coupled receptors: recent progress, challenges and future research, Int. J. Mol. Sci., 17, 95, 10.3390/ijms17010095 · DOI
- Wefers, 2014, Subgroup-specific localization of human medulloblastoma based on pre-operative MRI, Acta Neuropathol., 127, 931, 10.1007/s00401-014-1271-5 · DOI
- Zaiss, 1999, The proteasome inhibitor PI31 competes with PA28 for binding to 20S proteasomes, FEBS Lett., 457, 333, 10.1016/S0014-5793(99)01072-8 · DOI · Paper page
- Zhang, 2016, Integrated proteogenomic characterization of human high-grade serous ovarian cancer, Cell, 166, 755, 10.1016/j.cell.2016.05.069 · DOI · Paper page
- Zhang, 2004, Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment, Mol. Cell, 13, 341, 10.1016/S1097-2765(04)00050-4 · DOI · Paper page
- Zomerman, 2018, Identification of two protein-signaling states delineating transcriptionally heterogeneous human medulloblastoma, Cell Rep., 22, 3206, 10.1016/j.celrep.2018.02.089 · DOI
- Zuckermann, 2015, Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling, Nat. Commun., 6, 7391, 10.1038/ncomms8391 · DOI · Paper page
Cited by
Northcott, P. A., Robinson, G. W., Kratz, C. P., Mabbott, D. J., Pomeroy, S. L., Clifford, S. C., Rutkowski, S., Ellison, D. W., Malkin, D., Taylor, M. D., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0063-6 · Cited by 649
Self-citationRecent advances in mass spectrometry based clinical proteomics: applications to cancer research
Macklin, A., Khan, S., & Kislinger, T. (2020) · Clinical Proteomics · doi:10.1186/s12014-020-09283-w · Cited by 317
Sharma, T., Schwalbe, E. C., Williamson, D., Sill, M., Hovestadt, V., Mynarek, M., Rutkowski, S., Robinson, G. W., Gajjar, A., Cavalli, F., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02020-0 · Cited by 310
Self-citationMedulloblastomics revisited: biological and clinical insights from thousands of patients
Hovestadt, V., Ayrault, O., Swartling, F. J., Robinson, G. W., Pfister, S. M., & Northcott, P. A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0223-8 · Cited by 271
Self-citationCancer proteogenomics: current impact and future prospects
Mani, D. R., Krug, K., Zhang, B., Satpathy, S., Clauser, K. R., Ding, L., Ellis, M., Gillette, M. A., & Carr, S. A. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00446-5 · Cited by 229
The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein
Lucas, L. M., Dwivedi, V., Senfeld, J. I., Cullum, R. L., Mill, C. P., Piazza, J. T., Bryant, I. N., Cook, L. J., Miller, S. T., Lott, J. H., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000381 · Cited by 70
“Surprisingly, this report did not indicate that ERBB2 expression was elevated in the group 4 tumors, raising questions about the mechanism by which ERBB4 may be coupled to tumorigenesis or tumor progression in group 4 medulloblastomas (Forget et al., 2018; Rahmann and Gilbertson, 2018).”
BackgroundKameda-Smith, M. M., Zhu, H., Luo, E.-C., Suk, Y., Xella, A., Yee, B., Chokshi, C., Xing, S., Tan, F., Fox, R. G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35118-3 · Cited by 7
Self-citation
Metadata
- Authors
- Forget, A., Martignetti, L., Puget, S., Calzone, L., Brabetz, S., Picard, D., Montagud, A., Liva, S., Sta, A., Dingli, F., Arras, G., Rivera, J., Loew, D., Besnard, A., Lacombe, J., Pagès, M., Varlet, P., Dufour, C., Yu, H., Mercier, A. L., Indersie, E., Chivet, A., Leboucher, S., Sieber, L., Beccaria, K., Gombert, M., Meyer, F. D., Qin, N., Bartl, J., Chavez, L., Okonechnikov, K., Sharma, T., Thatikonda, V., Bourdeaut, F., Pouponnot, C., Ramaswamy, V., Korshunov, A., Borkhardt, A., Reifenberger, G., Poullet, P., Taylor, M. D., Kool, M., Pfister, S. M., Kawauchi, D., Barillot, E., Remke, M., & Ayrault, O.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 34
- Issue
- 3
- Pages
- 379-395.e7
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2892282588
- Cited by
- 142
- References
- 25
- FWCI
- 8.59
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 375 d)
- Funders
- ITMO Cancer
- Paris Alliance of Cancer Research Institutes
- Ministère Français de l'Enseignement Supérieur et de la Recherche
- Fondation de France
- King Baudouin Foundation
- Fondation ARC pour la Recherche sur le Cancer (20141201848)
- Ligue Nationale Contre le Cancer
- CNRS
- Institut Curie
- Région Ile-de-France (2013-2-EML-02-ICR-1)
- Deutsche Forschungsgemeinschaft (KA 4472/1-1)
- Fondation pour la Recherche Médicale (DGE20121125630)
- Brain Tumor Charity Collaborative Team (GN-000356)
- Pediatric Brain Tumor Foundation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.